In line with updated guidance from the GPhC and the CQC, we will only accept prescriptions for weight loss medications from prescribers who are registered with the CQC (Pharmacists are exempt from this guidance)
* To prescribe Mounjaro, you must provide a valid CQC provider registration number, this has to be provided to us by the prescriber.
* Prescriptions for weight loss medication will not be dispensed unless a verified CQC number is held on the prescriber's account account.
* The prescriber also is required to input the BMI of the patient in the prescrption notes, if this is not present it might delay your order being shipped, as we contact the prescriber for the BMI.
Mounjaro is a prescription only medicine indicated for: the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy or in addition to other medicinal products. weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/ m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus) Practitioners please note: Additional safe guides:- when prescribing Mounjaro adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.
Key features: Mounjaro is a prescription only medicine indicated for:
- the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy or in addition to other medicinal products.
- weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of
≥ 30 kg/ m2 (obesity) or
≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
Mechanism of action:
Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes.
In addition, both GIP and GLP-1 receptors are expressed in the areas of the brain important to appetite regulation. Tirzepatide is highly selective to human GIP and GLP-1 receptors. Tirzepatide has high affinity to both the GIP and GLP-1 receptors.
Tirzepatide lowers body weight and body fat mass. The mechanisms associated with body weight and body fat mass reduction involve decreased food intake through the regulation of appetite and modulation of fat utilisation.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients.
Store in a refrigerator at 2–8°C.
Needles included with every order.
Practitioners please note:
When prescribing Mounjaro adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard
EMC: https://www.medicines.org.uk/emc/product/15481/smpc#about-medicine
Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.15481.pdf
User manual: https://www.medicines.org.uk/emc/files/usermanual.15481.pdf
